ReviewCancer biology & medicine2020
Triple negative breast cancer: special histological types and emerging therapeutic methods.
Review in Cancer biology & medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 77 citations in OpenAlex.
- A phase II study of a doublet metronomic chemotherapy regimen consisting of oral vinorelbine and capecitabine in Chinese women with HER2-negative metastatic breast cancer.Thoracic cancer · 2023Trial
- Computational Identification of New Dual PAK4 and NAMPT Inhibitors.International journal of molecular sciences · 2026Article
- The effect of adjuvant radiotherapy on M0 adenoid cystic carcinoma of the breast: a retrospective cohort study based on SEER data.Gland surgery · 2025Article
- A rare ER-positive secretory breast carcinoma: diagnostic challenges and surgical treatment.Annals of medicine and surgery (2012) · 2025Article
- Machine learning and single-cell analysis uncover distinctive characteristics of CD300LG within the TNBC immune microenvironment: experimental validation.Clinical and experimental medicine · 2025Article
- Benzimidazole Derivatives in Breast Cancer: Target-Specific Therapeutic Breakthroughs.Current topics in medicinal chemistry · 2025Review
- Targeting low-risk triple-negative breast cancer: a review on de-escalation strategies for a new era.Translational breast cancer research : a journal focusing on translational research in breast cancer · 2025Review
- Multi-omics analysis identifies the unique high-FDCSP basal cells in triple-negative breast cancer.Experimental biology and medicine (Maywood, N.J.) · 2025Article
- Pentagalloyl Glucose fromPharmaceuticals (Basel, Switzerland) · 2024Article
- Impact of Neoadjuvant Therapy on PD-L1 Expression in Triple-Negative Breast Cancer and Correlation with Clinicopathological Factors.Diagnostics (Basel, Switzerland) · 2024Article
- Impact of Nanomedicine in Women's Metastatic Breast Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Review
- Updated Austrian treatment algorithm for metastatic triple-negative breast cancer.Wiener klinische Wochenschrift · 2024Review
- Prognostic Value of "Basal-like" Morphology, Tumor-Infiltrating Lymphocytes and Multi-MAGE-A Expression in Triple-Negative Breast Cancer.International journal of molecular sciences · 2024Article
- Association of molecular subtypes and treatment with survival in invasive micropapillary breast cancer: an analysis of the Surveillance, Epidemiology, and End Results database.Breast cancer (Tokyo, Japan) · 2024Article
- Cytoskeleton remodeling induced by SMYD2 methyltransferase drives breast cancer metastasis.Cell discovery · 2024Article
- Mapping the function of MicroRNAs as a critical regulator of tumor-immune cell communication in breast cancer and potential treatment strategies.Frontiers in cell and developmental biology · 2024Review
- Recent Advances of Multifunctional PLGA Nanocarriers in the Management of Triple-Negative Breast Cancer.AAPS PharmSciTech · 2023Review
- The dual-crosslinked prospective values of RAI14 for the diagnosis and chemosurveillance in triple negative breast cancer.Annals of medicine · 2023Article
- A Study on the Factors and Prediction Model of Triple-Negative Breast Cancer for Public Health Promotion.Diagnostics (Basel, Switzerland) · 2023Article
- Advances in Early Breast Cancer Risk Profiling: From Histopathology to Molecular Technologies.Cancers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Triple negative breast cancer (TNBC) is a complex and malignant breast cancer subtype that lacks expression of the estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2), thereby making therapeutic targeting difficult. TNBC is generally considered to have high malignancy and poor prognosis. However, patients diagnosed with certain rare histomorphologic subtypes of TNBC have better prognosis than those diagnosed with typical triple negative breast cancer. In addition, with the discovery and development of novel treatment targets such as the androgen receptor (AR), PI3K/AKT/mTOR and AMPK signaling pathways, as well as emerging immunotherapies, the therapeutic options for TNBC are increasing. In this paper, we review the literature on various histological types of TNBC and focus on newly developed therapeutic strategies that target and potentially affect molecular pathways or emerging oncogenes, thus providing a basis for future tailored therapies focused on the mutational aspects of TNBC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.